Preclinical development of innovative mRNA/MVA vaccines against SARS-CoV2

Resumen del proyecto

The purpose of this project is to design and test in preclinical studies a new vaccine against SARS-CoV2. The overall objective: 1. In a first step, to test a new mRNA vaccine candidate encoding SARS-CoV2 epitopes selected through a bioinformatic approach and co-formulated with nanoparticles (mRNA-CoV2) in vitro and in vivo to assess the potential to induce SARS-CoV2-specific immune responses. 2. In a second step, to test if a prime-boost strategy with mRNA-CoV2 prime and MVA-CoV2 boost induce higher immune responses as compared with mRNA-CoV2 alone.

Palabras clave

vacuna
RNAm
ARNm
epítopos SARS-CoV-2
bioinformática
nanopartículas
respuesta inmunitaria
COVID-19
SARS-CoV-2

Convocatoria

Acción Estratégica en Salud (AES)

Periodo de ejecución

30/10/2021 - 31/01/2022

Investigador Principal

FELIPE GARCIA ALCAIDE

Centro beneficiario

INSTITUTO DE INVESTIGACIONES BIOMEDICAS AUGUST PI I SUNYER (IDIBAPS)

Centro de realización

INSTITUTO DE INVESTIGACIONES BIOMEDICAS AUGUST PI I SUNYER (IDIBAPS)

Comunidad Autónoma

CATALUÑA

Provincia

BARCELONA

Financiación

550,000 €